# A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

> **NCT02782663** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 107 (actual)

## Conditions studied

- Crohn's Disease (CD)

## Interventions

- **DRUG:** ABT-494

## Key facts

- **NCT ID:** NCT02782663
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-18
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782663, "A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02782663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*